KLRS Allovir, Inc.

Nasdaq allovir.com


$ 4.91 $ -0.17 (-3.33 %)    

Wednesday, 15-Oct-2025 18:08:52 EDT
QQQ $ 605.45 $ 0.00 (0 %)
DIA $ 464.36 $ 0.00 (0 %)
SPY $ 667.65 $ 0.00 (0 %)
TLT $ 90.94 $ 0.00 (0 %)
GLD $ 389.90 $ 0.00 (0 %)
$ 4.93
$ 5.12
$ 4.70 x 2
$ 4.99 x 20
-- - --
$ 2.14 - $ 24.15
87,633
na
92.2M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-07-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-15-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-10-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 09-02-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate o...

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate o...

Core News & Articles

William Blair analyst Lachlan Brown initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperform rating.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION